Main Industry
Biotechnology
Main Product/Service
1. CA301L Glaucoma: Our glaucoma medication delivers optimal intraocular pressure (IOP)-lowering efficacy with minimal dosing frequency. We have also introduced the first generic alternative, providing patients with a highly effective, convenient, and cost-effective treatment option.
2. CA202L Glaucoma: Our patented, preservative-free formulation is gentle and non-damaging to the cornea, while improved excipients enhance comfort and allow for room-temperature storage, thereby increasing patient compliance. The potential efficacy of this new formulation extends to fundus diseases (such as eye stroke). Patent applications have been filed in 12 countries, and the formulation also alleviates dry eye symptoms, offering patients a more comprehensive ocular health solution.
3. CA201A Cataract: This innovative drug addresses unmet medical needs by protecting corneal endothelial cells and reducing the risk of corneal transplant complications. It can be co-administered with post-cataract surgery medications (such as antibiotics and steroids) to enhance therapeutic outcomes. Utilizing a drug repurposing strategy, it offers high safety while innovatively developing new formulations, new routes of administration, and new indications. Having overcome stability barriers, patent applications are currently being prepared to secure our technological advantage.
2. CA202L Glaucoma: Our patented, preservative-free formulation is gentle and non-damaging to the cornea, while improved excipients enhance comfort and allow for room-temperature storage, thereby increasing patient compliance. The potential efficacy of this new formulation extends to fundus diseases (such as eye stroke). Patent applications have been filed in 12 countries, and the formulation also alleviates dry eye symptoms, offering patients a more comprehensive ocular health solution.
3. CA201A Cataract: This innovative drug addresses unmet medical needs by protecting corneal endothelial cells and reducing the risk of corneal transplant complications. It can be co-administered with post-cataract surgery medications (such as antibiotics and steroids) to enhance therapeutic outcomes. Utilizing a drug repurposing strategy, it offers high safety while innovatively developing new formulations, new routes of administration, and new indications. Having overcome stability barriers, patent applications are currently being prepared to secure our technological advantage.
The content above was translated by Ai
Founded Year
2023
Unified Business No.
82985273
Status
Active
Number of Employees
5
Total Paid-in
Capital
61,738,500 (NT$)
Location of Company
Taiwan
, Taipei City
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Caravel Oculus INC. was founded by a professional team with experience in pharmaceutical marketing, focusing on the research and development of ophthalmic drugs. In a pragmatic and highly efficient manner, we advance treatment options for unmet clinical needs, committed to providing safe, effective, and clinically valuable new drug products to improve the quality of life for patients with eye diseases worldwide. Our mission is to be guided by clinical needs, leverage existing drug ingredients and innovative formulation strategies to accelerate the development of promising new ophthalmic drugs, and collaborate with industry, academia, and research sectors to explore more therapeutic possibilities.
The content above was translated by Ai
